Parkinson's Disease Trial, By Invitation NCT05779475 Sponsor: Novo Nordisk A/S Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, By Invitation

NCT05779475
By Invitation Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged 50 to 68 years old (inclusive) at the time of signing the consent form, either male or female.
  • People who have been diagnosed with Parkinson's disease using a specific set of recognised diagnostic guidelines (the Movement Disorder Society criteria), meeting the definition of "clinically probable" Parkinson's disease.
  • People with a moderate level of Parkinson's disease, based on specific clinical rating scales assessed by the study doctor when the person is in an "off" state (when medication is not working well).
  • People whose Parkinson's disease symptoms are not well enough controlled by their current oral Parkinson's medications, meaning they experience both "on" periods (when medication works) and "off" periods (when it does not), as assessed by the study doctor.
  • People who were diagnosed with Parkinson's disease more than 5 years ago but no more than 12 years ago at the time of signing the consent form.
  • People considered a possible future candidate for a cell therapy transplant procedure, as determined by the study doctor.
  • People whose life expectancy is assessed by the study doctor as greater than 7 years.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose parkinsonism (Parkinson's-like symptoms) is thought to be caused by something other than Parkinson's disease itself, or who have an atypical or secondary form of the condition, as determined by the study doctor.
  • People who have significant involuntary movements (dyskinesias) caused by their Parkinson's medication, based on a specific movement rating scale, as determined by the study doctor.
  • People whose Parkinson's disease is primarily characterised by tremor (shaking), as determined by the study doctor.
  • People with memory or thinking difficulties that suggest early or existing dementia, or other significant cognitive problems, as assessed using a specific cognitive test or diagnostic guidelines, as determined by the study doctor.
  • People with a significant medical or mental health condition (for example, moderate-to-severe depression or psychosis) or any other illness that the study doctor considers would make participation unsuitable.
  • People who have received treatment for muscle stiffness or abnormal posturing (dystonia or spasticity) within the 3 months before the screening visit (note: Botox injections for a localised dystonia are permitted).
  • People with significant neurological symptoms that are not explained by their Parkinson's disease, including an active seizure disorder, as determined by the study doctor.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
5 April 2023
Est. completion
11 March 2030

Where this trial is recruiting

🇯🇵 Japan 🇸🇪 Sweden 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (motor score) in OFF state

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov